Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. - Wikidata - wikimedia - TriplyDB

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

http://www.wikidata.org/entity/Q35101419

about

Novel algorithm for non-invasive assessment of fibrosis in NAFLD NLRP3 inflammasome activation is required for fibrosis development in NAFLD.The Wide and Complex Field of NAFLD Biomarker Research: Trends.Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients.Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease.Effects of resveratrol, exercises and their combination on gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver

P2860

Q28289982-CA049EF8-F6C7-4158-8704-7C08586FA8DC Q35146713-670651B3-63A9-4BB4-9DA8-8AD6F259FAA7 Q36962085-F3EA2319-8F29-4EA6-82B7-D7A8509B2536 Q44561660-006C9810-9B3B-4FE0-B02B-4AB7A8AF478E Q44697151-155C8398-08CB-4BC1-8A22-38C99F967C2E Q45305677-66CDBAB8-0D99-4514-BF0C-DA04EF3E4D04 Q49287362-9CD44451-9855-4B31-A600-3B6BDA8F35DD Q58754705-6CAA0102-D1C8-4B7A-B634-B3901BB31889

P2860

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

http://www.wikidata.org/entity/Q35101419

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@ast

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@en

type

label

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@ast

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@en

prefLabel

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@ast

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@en

P1433

Q35101419-E7EE304D-954E-48CF-A1D2-C7B2CE19D5A9

P1476

Q35101419-6A4963DC-0190-40A2-A4FA-B7525A5F96F4

P2093

Q35101419-4AE92847-8DD0-4D7B-BE7C-ED40EED9C2DD

Q35101419-673B7B15-928A-43FD-AAE8-43024B5BD588

Q35101419-B31A770A-3FCF-43D9-8CE9-3F80269917BF

Q35101419-DBAAAB66-E947-46E0-982A-C35B402E584B

P2860

Q35101419-23E4A08D-8E40-4A2C-A828-610EB76D5EE3

Q35101419-4AA2ACE5-A326-4304-8FB2-7E484E158B0B

Q35101419-4C556BA6-6AA3-4D42-957A-DB48B4D344A4

Q35101419-4EFE9281-2239-4496-9F78-2DC906567E73

Q35101419-5D49C1AA-3DDC-4EC8-BB7A-8E180A2E0C4D

Q35101419-6C20EC28-1FD1-4B04-BE9B-DDF9CB03619A

Q35101419-729147CF-2D24-42E7-8562-409328AE64BC

Q35101419-7E784BA1-4189-4BBD-93E1-F4609B13A27B

Q35101419-841CE90A-EAC7-40E8-8B99-0F4D1C5D8BE7

Q35101419-84240FAB-F38F-4B57-B3F9-05C2FA60B3B3

P304

Q35101419-6E238FC0-9BD5-4D68-987C-8FF42BCFE1EB

P31

Q35101419-B0D78010-FED9-4F41-8E23-23E1EA015CD2

P356

Q35101419-2F2FDE09-2427-4634-A355-DCEA5C40430E

P478

Q35101419-6D80F895-EC85-49DF-B8F2-57260B26714C

P50

Q35101419-11EAFBF7-B2B9-4430-851F-E31FCF46E8F7

Q35101419-538D0C3F-DCEC-4CBF-9D8A-ACC696C409F3

Q35101419-79F785BC-E4C6-41AC-8B94-554298A23E54

P577

Q35101419-910351F2-0DAF-422B-980E-06E6230869EA

P5875

Q35101419-9A40571E-E569-4D52-8F50-A86EF16FF0FA

P698

Q35101419-6389A2AE-F72B-4BEC-967E-24D10CE28C68

P921

Q35101419-2DF5316E-5B94-47C2-A749-B92AC4CBAB84

Q35101419-9BC88EE1-E57C-4474-87A8-147611575683

P932

Q35101419-D5A5014C-6537-47C1-A688-AE44BEB0DC32

P356

P1433

Journal of Nutrition and Metabolism

P1476

Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.

@en

P2093

Hagen Kälsch

http://www.w3.org/2001/XMLSchema#string

Jochen Erhard

http://www.w3.org/2001/XMLSchema#string

Julia Kälsch

http://www.w3.org/2001/XMLSchema#string

Martin Schlattjan

http://www.w3.org/2001/XMLSchema#string

P2860

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.

Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

An apoptosis panel for nonalcoholic steatohepatitis diagnosis

Apoptosis: the nexus of liver injury and fibrosis.

Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.

Abnormalities of lipid metabolism in nonalcoholic fatty liver disease.

Novel insights into the pathophysiology of nonalcoholic fatty liver disease.

P304

369168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/369168

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P50

Lars P. Bechmann

P577

2011-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51505850

http://www.w3.org/2001/XMLSchema#string

P698

21773018

http://www.w3.org/2001/XMLSchema#string

P921

P932

3135053

http://www.w3.org/2001/XMLSchema#string